2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.08A.02 Adherence to Adjuvant Immunotherapy and Target Therapy Protocols Inpatients with Resected NSCLC: A Meta Analysis

Pdf Summary

The study conducted by Pietro Bertoglio and the LUMINA working group focused on evaluating adherence to adjuvant immunotherapy (IO) and target therapy (TT) protocols in patients with resected non-small cell lung cancer (NSCLC). This meta-analysis included seven studies with a total of 2479 patients, comprising both phase 2 and phase 3 trials.<br /><br />Key findings of the study include:<br />1. **Omission of Therapy**: A complete omission of adjuvant therapy occurred in only 1.0% of patients, indicating relatively high adherence in terms of some therapy being administered.<br />2. **Incomplete Therapy**: Approximately 38.0% of patients did not complete the originally planned number of therapy cycles, highlighting a significant issue in protocol adherence.<br />3. **Adverse Events (AEs)**: Severe adverse events were observed in 21.5% of patients, which underscores the treatment's potential side effects impacting protocol adherence.<br /><br />Results showed no significant differences between the immunotherapy and target therapy groups regarding the omission or incomplete therapy rates, as well as severe AEs. <br /><br />**Conclusion**: The study emphasizes that adherence to adjuvant therapy protocols post-surgery is crucial for NSCLC patients, yet challenging due to performance status post-surgery. High rates of incomplete therapies were noted, prompting a call for careful evaluation of the role and duration of adjuvant therapy to mitigate adverse events and improve adherence.<br /><br />**Background and Aim**: The treatment of NSCLC has been dramatically transformed with the introduction of IO and TT, yet adherence remains limited. The study aimed to assess adherence rates in recent trials involving these therapies post-surgery.<br /><br />**Methods**: The research involved a systematic review and meta-analysis of trials from PubMed and Embase up to March 2023, focusing on IO or TT in post-operative NSCLC patients. The primary outcomes were the rates of therapy omission, incompleteness, and severe AEs.<br /><br />This meta-analysis provides critical insights for optimizing adjuvant treatment strategies to address adherence obstacles effectively.

Asset Subtitle

Pietro Bertoglio

Meta Tag

Speaker Pietro Bertoglio

Topic Local-Regional Non-small Cell Lung Cancer

Keywords

adjuvant immunotherapy

target therapy

NSCLC

protocol adherence

meta-analysis

adverse events

therapy omission

incomplete therapy

post-surgery

treatment strategies